Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00178425 · ClinicalTrials.gov registry record · Phase 4
PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients
A Phase 4 study of Transplantation, Liver, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00178425: Completed Phase 4 study of Transplantation, Liver, sponsored by University of Rochester.
NCT00178425 is a Phase 4 study of Transplantation, Liver that has completed, run by University of Rochester. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00178425, a Phase 4 study of Transplantation, Liver, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight. While the deceased donor transplant receives the complete liver, in the live donor just over half of the liver is given (about 60%). The way these different types of transplants break down drugs could be different. Measuring the drug levels allows us to know what happens to the medication in between the morning and the evening dose.
Conditions Studied
Interventions
- PROCEDURE Serial blood sampling as described in protocol
- PROCEDURE Estimation of Creatinine Clearance at regular intervals
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
What the finished NCT00178425 record still lists
NCT00178425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Transplantation, Liver appearing as the primary indexed condition, and to 2 interventions - of which Serial blood sampling as described in protocol is the first listed.
NCT00178425 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00178425 about?
NCT00178425 is a clinical study titled "PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients". The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight. While the deceased donor transplant receives the complete liver, in the live donor just over half ...
What is the current status of trial NCT00178425?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2005-01. Estimated completion is 2006-06.
What conditions does trial NCT00178425 study?
This clinical trial studies the following conditions: Transplantation, Liver.
What interventions are being tested in trial NCT00178425?
The interventions under investigation include: Serial blood sampling as described in protocol (PROCEDURE), Estimation of Creatinine Clearance at regular intervals (PROCEDURE).
Who is sponsoring clinical trial NCT00178425?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00178425 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transplantation, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00178425's enrollment target sits among peer trials
24 1699th of 2000 higher than 277 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia